Christine Johnston says biosimilar interchangeability bills, plus 2026 PBM reforms, would force PBMs to justify preferring higher-cost brands.
|Slideshows|April 15, 2019
5 Myths About Biosimilars-And the Facts
Author(s)Nicholas Hamm
The falsehoods being spread about biosimilars that don’t match up with reality.
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
How common is atopic dermatitis in the US? Not nearly as common as other research has shown, according to this study
2
5 things you should know about the midterms and healthcare
3
The ripple effects of Medicare’s maximum fair price with Hiva Pourarsalan, Pharm.D. | AMCP Nexus 2026
4
Medicaid can't opt out of gene therapies, so planning matters more, says Katelyn Meyer, Pharm.D. | AMCP Nexus 2026
5